Overview

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Status:
Recruiting

Trial end date:
2036-02-17

Target enrollment:

Participant gender:

Summary

The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy

Phase:

Phase 1

Details

Lead Sponsor:

Celyad (formerly named Cardio3 BioSciences)
Celyad Oncology SA

Collaborator:

Novella Clinical

Treatments:

Fluorouracil
Oxaliplatin